Top

Journal of Autism and Developmental Disorders

Gepubliceerd in:

14-11-2019 | Brief Report

Buspirone for the Treatment of Generalized Anxiety Disorder in Williams Syndrome: A Case Series

Auteurs: Robyn P. Thom, Christopher J. Keary, Jessica L. Waxler, Barbara R. Pober, Christopher J. McDougle

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 2/2020

Abstract

Co-morbid anxiety disorders, including generalized anxiety disorder (GAD), are highly prevalent among individuals with Williams syndrome (WS). However, reports of the pharmacologic treatment of only a limited number of previous anxiety disorders in WS have appeared in the literature. Here, we review the case histories of three adolescents/young adults with WS and the treatment course of co-morbid GAD with buspirone. Treatment with buspirone was well-tolerated and resulted in sustained response in all three cases. Common medical disorders in WS are highlighted with regards to safe and appropriate pharmacologic treatment of GAD. Buspirone’s generally benign side effect profile is a major benefit of its use for treating GAD in individuals with WS.

vorige artikel Short Report: Social Perception of High School Students with ASD in Norway

volgende artikel What About the Other Side of Double Empathy? A Response to Alkhaldi, Sheppard and Mitchell’s JADD Article Concerning Mind-Reading Difficulties in Autism

Alexander, A., Gallagher, A., Pober, B., Waxler, J., & McDougle, C. (2019). Post-traumatic stress disorder following cardiac surgery: A case report of a nine-year-old female with Williams syndrome. Journal of Intellectual & Developmental Disability,44(2), 244–247.CrossRef

Beach, S. R., Celano, C. M., Sugrue, A. M., Adams, C., Ackerman, M. J., Noseworthy, P. A., et al. (2018). QT prolongation, Torsades de Pointes, and psychotropic medications: A 5-year update. Psychosomatics,59(2), 105–122. https://doi.org/10.1016/j.psym.2017.10.009.CrossRefPubMed

Bergman, J., Roof, R. A., Furman, C. A., Conroy, J. L., Mello, N. K., Sibley, D. R., et al. (2013). Modification of cocaine self-administration by buspirone (buspar^®): Potential involvement of D3 and D4 dopamine receptors. International Journal of Neuropsychopharmacology,16(2), 445–458. https://doi.org/10.1017/S1461145712000661.CrossRefPubMed

Buitelaar, J. K., van der Gaag, R. J., & van der Hoeven, J. (1998). Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: Results of an open-label study. The Journal of Clinical Psychiatry,59(2), 56–59.CrossRef

Ceranoglu, T. A., Wozniak, J., Fried, R., Galdo, M., Hoskova, B., Fong, M. D., et al. (2018). A retrospective chart review of buspirone for the treatment of anxiety in psychiatrically referred youth with high-functioning autism spectrum disorder. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/cap.2018.0021.CrossRefPubMed

Chugani, D. C., Chugani, H. T., Wiznitzer, M., Parikh, S., Evans, P. A., Hansen, R. L., et al. (2016). Efficacy of low-dose buspirone for restricted and repetitive behavior in young children with autism spectrum disorder: A randomized trial. The Journal of Pediatrics,170(45–53), e1–e4. https://doi.org/10.1016/j.jpeds.2015.11.033.CrossRef

Collins, R. T. (2018). Cardiovascular disease in Williams syndrome. Current Opinion in Pediatrics,30(5), 609–615. https://doi.org/10.1097/MOP.0000000000000664.CrossRefPubMed

Collins, R. T., Aziz, P. F., Gleason, M. M., Kaplan, P. B., & Shah, M. J. (2010). Abnormalities of cardiac repolarization in Williams syndrome. The American Journal of Cardiology,106(7), 1029–1033. https://doi.org/10.1016/j.amjcard.2010.05.041.CrossRefPubMed

Dykens, E. M. (2003). Anxiety, fears, and phobias in persons with Williams Syndrome. Developmental Neuropsychology,23(1–2), 291–316. https://doi.org/10.1080/87565641.2003.9651896.CrossRefPubMed

Edwards, D. J., Chugani, D. C., Chugani, H. T., Chehab, J., Malian, M., & Aranda, J. V. (2006). Pharmacokinetics of buspirone in autistic children. The Journal of Clinical Pharmacology,46(5), 508–514. https://doi.org/10.1177/0091270006286903.CrossRefPubMed

Ewart, A. K., Morris, C. A., Atkinson, D., Jin, W., Sternes, K., Spallone, P., et al. (1993). Hemizygosity at the elastin locus in a developmental disorder, Williams syndrome. Nature Genetics,5(1), 11–16. https://doi.org/10.1038/ng0993-11.CrossRefPubMed

Feighner, J. P., Merideth, C. H., & Hendrickson, G. A. (1982). A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder. The Journal of Clinical Psychiatry,43(12 Pt 2), 103–108.PubMed

Guaiana, G., Barbui, C., & Cipriani, A. (2010). Hydroxyzine for generalised anxiety disorder. Cochrane Database of Systematic Reviews,12, CD006815. https://doi.org/10.1002/14651858.cd006815.pub2.CrossRef

Kim, Y.-M., Cho, J. H., Kang, E., Kim, G.-H., Seo, E.-J., Lee, B. H., et al. (2016). Endocrine dysfunctions in children with Williams-Beuren syndrome. Annals of Pediatric Endocrinology & Metabolism,21(1), 15–20. https://doi.org/10.6065/apem.2016.21.1.15.CrossRef

Leyfer, O. T., Woodruff-Borden, J., Klein-Tasman, B. P., Fricke, J. S., & Mervis, C. B. (2006). Prevalence of psychiatric disorders in 4 to 16-year-olds with Williams syndrome. American Journal of Medical Genetics Part B, Neuropsychiatric Genetics: The Official Publication of the International Society of Psychiatric Genetics,141B(6), 615–622. https://doi.org/10.1002/ajmg.b.30344.CrossRef

Martens, M. A., Seyfer, D. L., Andridge, R. R., Foster, J. E. A., Chowdhury, M., McClure, K. E., et al. (2012). Parent report of antidepressant, anxiolytic, and antipsychotic medication use in individuals with Williams syndrome: Effectiveness and adverse effects. Research in Developmental Disabilities,33(6), 2106–2121. https://doi.org/10.1016/j.ridd.2012.06.006.CrossRefPubMed

Martens, M. A., Wilson, S. J., & Reutens, D. C. (2008). Research Review: Williams syndrome: a critical review of the cognitive, behavioral, and neuroanatomical phenotype. Journal of Child Psychology and Psychiatry,49(6), 576–608. https://doi.org/10.1111/j.1469-7610.2008.01887.x.CrossRef

Mervis, C. B., Robinson, B. F., Bertrand, J., Morris, C. A., Klein-Tasman, B. P., & Armstrong, S. C. (2000). The Williams syndrome cognitive profile. Brain and Cognition,44(3), 604–628. https://doi.org/10.1006/brcg.2000.1232.CrossRefPubMed

Morris, C. A. (1993). Williams Syndrome. GeneReviews^®. Retrieved January 23, 2019, from http://www.ncbi.nlm.nih.gov/pubmed/20301427.

Pariente, A., de Gage, S. B., Moore, N., & Bégaud, B. (2016). The benzodiazepine-dementia disorders link: Current state of knowledge. CNS Drugs,30(1), 1–7. https://doi.org/10.1007/s40263-015-0305-4.CrossRefPubMed

Pecknold, J. C., Matas, M., Howarth, B. G., Ross, C., Swinson, R., Vezeau, C., et al. (1989). Evaluation of buspirone as an antianxiety agent: Buspirone and diazepam versus placebo. Canadian Journal of Psychiatry. Revue canadienne de psychiatrie,34(8), 766–771.CrossRef

Pober, B. R. (2010). Williams-Beuren syndrome. The New England Journal of Medicine,362(3), 239–252. https://doi.org/10.1056/NEJMra0903074.CrossRefPubMed

Realmuto, G. M., August, G. J., & Garfinkel, B. D. (1989). Clinical effect of buspirone in autistic children. Journal of Clinical Psychopharmacology,9(2), 122–125.CrossRef

Royston, R., Howlin, P., Waite, J., & Oliver, C. (2017). Anxiety disorders in Williams syndrome contrasted with intellectual disability and the general population: A systematic review and meta-analysis. Journal of Autism and Developmental Disorders,47(12), 3765–3777. https://doi.org/10.1007/s10803-016-2909-z.CrossRefPubMed

Schatzberg, A., & DeBattista, C. (2015). Manual of clinical psychopharmacology (8th ed.). Arlington, VA: American Psychiatric Publishing Inc.CrossRef

Solmi, M., Murru, A., Pacchiarotti, I., Undurraga, J., Veronese, N., Fornaro, M., et al. (2017). Safety, tolerability, and risks associated with first- and second-generation antipsychotics: A state-of-the-art clinical review. Therapeutics and Clinical Risk Management,13, 757–777. https://doi.org/10.2147/TCRM.S117321.CrossRefPubMedPubMedCentral

Sramek, J. J., Frackiewicz, E. J., & Cutler, N. R. (1997). Efficacy and safety of two dosing regimens of buspirone in the treatment of outpatients with persistent anxiety. Clinical Therapeutics,19(3), 498–506.CrossRef

Strømme, P., Bjømstad, P. G., & Ramstad, K. (2002). Prevalence estimation of Williams syndrome. Journal of Child Neurology,17(4), 269–271. https://doi.org/10.1177/088307380201700406.CrossRefPubMed

The Pediatric Anxiety Rating Scale (PARS): Development and psychometric properties. (2002). Journal of the American Academy of Child and Adolescent Psychiatry, 41(9), 1061–1069. Retrieved August 19, 2019, from http://www.ncbi.nlm.nih.gov/pubmed/12218427.

Urgeles, D., Alonso, V., & Ramos-Moreno, T. (2013). Neuropsychiatric and behavioral profiles of 2 adults with Williams syndrome: Response to antidepressant intake. Primary Care Companion to the Journal of Clinical Psychiatry. https://doi.org/10.4088/pcc.13m01504.CrossRef

Wenzel-Seifert, K., Wittmann, M., & Haen, E. (2011). QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. Deutsches Arzteblatt International,108(41), 687–693. https://doi.org/10.3238/arztebl.2011.0687.CrossRefPubMedPubMedCentral

Woodruff-Borden, J., Kistler, D. J., Henderson, D. R., Crawford, N. A., & Mervis, C. B. (2010). Longitudinal course of anxiety in children and adolescents with Williams syndrome. American Journal of Medical Genetics Part C: Seminars in Medical Genetics,154C(2), 277–290. https://doi.org/10.1002/ajmg.c.30259.CrossRef

Titel: Buspirone for the Treatment of Generalized Anxiety Disorder in Williams Syndrome: A Case Series
Auteurs: Robyn P. Thom
Christopher J. Keary
Jessica L. Waxler
Barbara R. Pober
Christopher J. McDougle
Publicatiedatum: 14-11-2019
Uitgeverij: Springer US
Gepubliceerd in: Journal of Autism and Developmental Disorders / Uitgave 2/2020
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI: https://doi.org/10.1007/s10803-019-04301-9

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen

Andere artikelen Uitgave 2/2020

Adaptive Behavior Moderates Health-Related Pathways in Children with Autism Spectrum Disorder

A Relation Between Autism Traits and Gender Self-concept: Evidence from Explicit and Implicit Measures

Comparing the Psychometric Properties of the Self- and Parent-Report Versions of Autism-Spectrum Quotient-Adult in Hong Kong (AQ-Adult-HK)

Ask the Editor: What is the Most Appropriate Way to Talk About Individuals with a Diagnosis of Autism?

An On-Line Survey of University Students with Autism Spectrum Disorder in Australia and New Zealand: Characteristics, Support Satisfaction, and Advocacy

Brief Report: Me, Reporting on Myself: Preliminary Evaluation of the Criterion-Related Validity of the Theory of Mind Inventory-2 when Completed by Autistic Young Adults